What EU 'Killer Acquisition' Study Means For Pharma Deals
On April 10, the European Commission's Directorate-General for Competition held an expert workshop to discuss its commissioned ex-post evaluation study into so-called killer acquisitions in the pharmaceutical sector, published on Nov....To view the full article, register now.
Already a subscriber? Click here to view full article